Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy

Antonella Castagna, Laura Galli, Carlo Torti, Antonella D Arminio Monforte, Cristina Mussini, Andrea Antinori, Alessandro Cozzi-Lepri, Nicoletta Ladisa, Andrea De Luca, Elena Seminari, Nicola Gianotti, Adriano Lazzarin

Research output: Contribution to journalArticle

Abstract

Background: The extent of short-term CD4+ T-cell recovery in patients tolerating first-line highly active antiretroviral therapy (HAART) and attaining undetectable HIV RNA levels is inadequately defined. Methods: We retrospectively analysed patients In four Italian cohorts who started HAART between January 1996 and September 2006. All patients had known HCV coinfection status, did not modify the regimen for 6 months and had + T-cell counts were 226 cells/μl (IQR 99-332), CD4+ T-cell percentages were 14.7% (IQR 8.7-21.2) and HIV RNA levels were 4.91 log10 copies/ml (IQR 4.38-5.34). Overall, 24-week CD4+ T-cell recovery was 144 cells/μl (IQR 70-240). At multivariable analysis, T-cell recovery was positively related to the use of a boosted protease Inhibitor (P+ T-cells (P+/CD8+ T-cell ratio and a history of AIDS-defining events had no independent effect on CD4+ T-cell recovery. Conclusions: Among HIV-infected patients tolerating first-line HAART and with undetectable HIV RNA after 6 months, CD4+ T-cell recovery is significantly greater in those without HCV coinfection, with a high baseline viral load, a high baseline percentage of CD4+ T-cells and In those treated with a boosted protease Inhibitor.

Original languageEnglish
Pages (from-to)165-175
Number of pages11
JournalAntiviral Therapy
Volume15
Issue number2
DOIs
Publication statusPublished - 2010

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Predicting the magnitude of short-term CD4<sup>+</sup> T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy'. Together they form a unique fingerprint.

  • Cite this